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The Kraepelinian dichotomy posits that patients with schizophrenia (SCZ) and bipolar disor-
der (BD) present as two separate psychotic entities such that they differ in terms of clinical
severity including neurocognitive functioning. Our study aimed to specifically compare and
contrast the level of neurocognitive functioning between SCZ and BD patients and identify
predictors of their poor neurocognitive functioning.We hypothesized that patients with SCZ
had a similar level of neurocognitive impairment compared with BD. About 49 healthy con-
trols (HC), 72 SCZ, and 42 BD patients who were matched for age, gender, and premorbid
IQ were administered the Brief Assessment of Cognition battery (BAC). Severity of psy-
chopathology and socio-occupational functioning were assessed for both patients groups.
Both BD and SCZ groups demonstrated similar patterns of neurocognitive deficits across
several domains (verbal memory, working memory, semantic fluency, processing speed)
compared with HC subjects. However, no significant difference was found in neurocogni-
tive functioning between BD and SCZ patients, suggesting that both patient groups suffer
the same degree of neurocognitive impairment. Patients with lower level of psychoso-
cial functioning [F (1,112)=2.661, p=0.009] and older age [F (1,112)=−2.625, p= 0.010], not
diagnosis or doses of psychotropic medications, predicted poorer overall neurocognitive
functioning as measured by the lower BAC composite score. Our findings of comparable
neurocognitive impairments between SCZ and BD affirm our hypothesis and support less
the Kraepelinian concept of dichotomy but more of a continuum of psychotic spectrum
conditions. This should urge clinicians to investigate further the underlying neural basis of
these neurocognitive deficits, and be attentive to the associated socio-demographic and
clinical profile in order to recognize and optimize early the management of the widespread
neurocognitive deficits in patients with SCZ and BD.
Keywords: schizophrenia, bipolar disorder, Kraepelinian dichotomy, neurocognitive functions, psychosocial func-
tioning, psychotic spectrum
INTRODUCTION
The Kraepelinian dichotomy, a prominent paradigm in psychia-
try, has influenced nosology for severe psychiatric disorders such as
schizophrenia (SCZ) and bipolar disorder (BD) within diagnostic
classification systems including the Diagnostic Statistical Manual
of Mental Disorders and the International Classification of Dis-
eases for many decades (1, 2). The paradigm posits that patients
with dementia praecox (SCZ) and manic depression (BD) present
as two separate psychotic disorders (3, 4). Evidence in support of
the Kraepelinian notion includes volumetric neuroimaging dif-
ferences in brain regions such as the amygdala, hippocampus, and
lateral ventricles that appear to be disorder-specific (5–7). In addi-
tion, unlike BD, reduced gray matter volumes and neurocognitive
neuromotor impairments occur in the prodromal stage of SCZ
despite both having early onset of illness during adolescence and
recent findings of common genetic predisposition in BD and SCZ
(6, 8–13). Furthermore, patients with SCZ are thought to suf-
fer more extensive brain morphological abnormalities and more
severe neurocognitive deficits in comparison with patients with BD
(14–18). Other than the apparent empirical evidence, the Krae-
pelinian dichotomy is appealing clinically due to its conceptual
and diagnostic simplicity (19, 20).
However, several issues challenge the dichotomous paradigm
of psychotic disorders with respect to SCZ and BD. These issues
include the overlapping organic basis and blurred boundaries
between psychoses from emerging biological data (21, 22), the
non-specificity of psychopathological features such as percep-
tual disturbances and affective symptoms between SCZ and BD,
and the shared genetic susceptibility loci uncovered within recent
genome-wide association studies (GWAS) (23, 24). Accumulat-
ing evidence from clinical observations, antipsychotic treatment,
and findings of neurocognitive functioning in SCZ and BD fur-
ther argued against the Kraepelinian dichotomy. First, clinicians
frequently encounter patients who do not fall neatly into either cat-
egory, such as individuals with schizoaffective disorders and BD
patients with prominent psychotic symptoms. Second, dopamine
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dysregulation has been implicated in both disorders, making
antipsychotic drugs useful in the management of SCZ as well
as BD (6, 8). Third, with regards to neurocognitive functioning,
extant studies have reported poorer neurocognitive functioning
in patients with SCZ compared to those with BD, but there are
also data suggesting that patients with SCZ are comparable with
BD patients in terms of neurocognitive impairments (14, 25–31).
These inconsistent findings on neurocognitive functioning may be
due to differences in sample size, specific neurocognitive deficits
measured, type of scales used, and presence of other confounders
including age and premorbid intelligence (26, 27, 30, 32).
Thus, in this study, we aimed to specifically compare and con-
trast the level of neurocognitive functioning between patients with
SCZ and BD as well as identify predictors of poor neurocognitive
functioning in these patients. Based on clinical impression within
a tertiary psychiatric hospital context and extant data, we hypoth-
esized that patients with SCZ had a similar level of neurocognitive
impairment compared with BD and the neurocognitive impair-
ment is associated with particular socio-demographic and clinical
factors after taking into account premorbid intelligence, level of
education, and psychotropic medications prescribed.
MATERIALS AND METHODS
PARTICIPANTS
The cross-sectional study sample comprised of a total of 163 par-
ticipants [72 patients diagnosed with SCZ, 42 patients with BD,
and 49 healthy controls (HC)] who gave their written informed
consent to participate in the study after a detailed explanation of
the study procedures. Patients with SCZ and BD were recruited
from the outpatient settings of the Institute of Mental Health,
Singapore. All diagnoses were confirmed by a psychiatrist (Kang
Sim) using information obtained from the existing medical record,
clinical history, mental status examination, interviews with the
patients and their significant others as well as the administration of
the Structured Clinical Interview for DSM-IV disorders – Patient
Version (SCID-I/P) (33). All patients were maintained on a sta-
ble dose of psychotropic medication for at least 2 weeks prior to
the recruitment and did not have their medication withdrawn for
the purpose of the study. HC were administered the Structured
Clinical Interview for DSM-IV disorders – Non-Patient Version
(SCID-I/NP) (34). None of the participants had a history of signif-
icant and/or unstable/untreated medical illnesses such as seizure
disorder, head trauma, or cerebrovascular accidents. Moreover, no
subjects had a current or past history of substance use or alcohol
use disorder. This study was approved by the Institutional Review
Boards of the Institute of Mental Health, Singapore.
NEUROCOGNITIVE ASSESSMENT
The brief assessment of cognition battery
The Brief Assessment of Cognition (BAC) battery (35) was admin-
istered to all subjects. The subjects were randomly assigned to a
sequence of BAC version A and B. The BAC scales include:
1. Verbal memory task – a subject was given 5 attempts to
remember 15 words and recall as many words as possible;
2. Digit sequencing task – a subject was presented with clusters of
numbers of increasing length and then asked to repeat in order
from the lowest to highest length;
3. Token motor task – a subject was given 100 plastic tokens and
asked to place 2 tokens at a time within a container as quickly
as possible within 60 s;
4. Verbal fluency – divided into semantic and letter fluency,
whereby a subject was asked to name as many words as pos-
sible within a specific category (e.g., supermarket items), and
to name words that begin with a specific letter (e.g., F and S)
within 60 s, respectively;
5. Symbol coding task – a subject was asked to write matching
numbers from 1 to 9 to symbols within 90 s;
6. Tower of London – as an example, a subject was shown two
pictures of three balls of different colors arranged on three dif-
ferent pegs, whereby the balls were arranged differently on each
picture and the subjects were asked to give the total number of
times the balls in one picture needed to be moved in order to
end with the arrangement in the other picture.
We divided the token motor task into two measures, namely
the number of tokens correctly placed into a container (tokens
correct) and the number of tokens left after 60 s (tokens left).
Although both measures tap motor speed function, tokens correct
measure did not credit the subjects for tokens put into container
incorrectly (i.e., not picked up and placed at the same time) which
required eye-hand coordination and precision in order to perform
the task correctly. Digit sequencing task, token motor task, sym-
bol coding, and Tower of London measured working memory,
motor speed, attention, and speed of information processing and
executive functioning respectively (35, 36).
Wide range achievement test (reading scale)
The wide range achievement test (WRAT) (37) reading subscale
was used to measure premorbid intelligence in all the subjects.
CLINICAL ASSESSMENTS
Global assessment of functioning
The global assessment of functioning (GAF) (38) rated (from 0
to 90) the severity of symptoms, disability, and the total level of
social and occupational functioning. The GAF was administered
to both SCZ and BD groups.
Positive and negative syndrome scale
The positive and negative syndrome scale (PANSS) (39) allowed
characterization and quantification of psychotic psychopathology.
The scale has 7 items for positive symptoms, 7 items for negative
symptoms, and 16 items for general psychopathology. The PANSS
was administered to SCZ and BD patients.
Young mania rating scales
The Young mania rating scales (YMRS) (40) contains 11 items
which were used to measure the severity of manic symptoms in
BD patients. There are four items that are graded on a 0–8 scale
(irritability, speech, thought content, and disruptive/aggressive
behavior). The remaining seven items are graded on a 0–4 scale.
The YMRS scale was administered to SCZ and BD patients.
STATISTICAL ANALYSES
All statistical tests were performed using PASW for Windows,
version 18.0 (SPSS, Inc., Chicago, IL, USA). The normal-
ity of distributions of continuous measures was checked with
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the Kolmogorov–Smirnov one-sample test. Socio-demographic
variables were compared using two sample student t -tests and
F-test for continuous variables, and chi-square test for categor-
ical variables. Two-way analysis of covariance (ANCOVA) was
used to examine for any difference in neurocognitive functioning
(BAC task performance) between the groups after adjusting for
the covariates described below. We first compared the neurocog-
nitive measures between all three groups, HC vs. SCZ and HC vs.
BD, and adjusting for covariates of age, gender, years of educa-
tion, and premorbid IQ. We then specifically compared the BAC
item performance between SCZ and BD patients, by adjusting for
premorbid IQ, age, gender, years of education, and clinical char-
acteristics such as the duration of illness, duration of untreated
psychosis, GAF scores, PANSS composite scores, YMRS scores,
and antipsychotic dose in terms of mean daily chlorpromazine
(CPZ) mg equivalents. Stepwise linear regression analyses were
performed to determine predictors of neurocognitive functioning
in patients including socio-demographic (such as age, gender) and
clinical characteristics (such as diagnosis, duration of illness, GAF
scores, PANSS composite scores, YMRS scores, and antipsychotic
dose). The significance level for statistical tests was set at two tailed
p< 0.05.
RESULTS
SOCIO-DEMOGRAPHIC CHARACTERISTICS
Across the three subject groups (HC, SCZ, BD), there were sig-
nificant differences in subject’s and mother’s years of education
but there was no significant difference in age, sex, handedness,
and WRAT scores. Compared to patients with BD, patients with
SCZ had longer duration of untreated psychosis and lower level
of psychosocial functioning as reflected by the lower GAF scores.
There was no significant difference in age, gender, handedness,
years of education, WRAT scores, age of onset, and duration of
illness between SCZ and BD. The socio-demographic and clinical
features of the subjects are shown in Table 1.
NEUROCOGNITIVE FUNCTIONING
Table 2 showed the neurocognitive profile across the entire sub-
ject sample based on the BAC battery administration. HC subjects
scored the highest in all BAC items compared to SCZ and BD
patients. Compared to HC, patients with SCZ scored lower in
BAC tasks of verbal memory, semantic and letter fluency, digit
sequencing, tokens left, symbol coding, total BAC score indicat-
ing neurocognitive deficits in verbal memory and fluency, working
memory, motor speed, and attention. Compared to HC, patients
Table 1 | Demographic and clinical characteristics of the participants.
Characteristic HC (n=49) SCZ (n=72) BD (n=42) Statistical analysis
SCZ vs. BD All three groups
Mean SD Mean SD Mean SD t -test p F -test p
Age 31.9 10.4 31.47 8.29 32.57 9.673 −0.642 0.522 0.191 0.827
Subject’s years of education 13.59 1.62 12.31 2.039 12.15 2.291 0.364 0.717 7.849 0.001*
Father’s years of education 8.53 4.22 7.62 3.697 7.31 3.317 0.447 0.655 1.454 0.237
Mother’s years of education 7.88 4.29 6.93 3.815 4.98 4.129 2.551 0.012* 6.228 0.002*
WRAT scores 49.78 4.25 49.75 5.301 49.88 4.994 −0.13 0.897 0.75 0.474
Duration of illness – – 4.77 5.317 3.32 56.39 1.394 0.166 – –
Age of onset – – 26.69 8.073 28.24 9.294 −0.931 0.354 – –
Duration of untreated psychosis – – 1.715 2.206 0.296 0.528 4.094 <0.001* – –
Mean daily CPZ mg equivalents – – 185.76 197.47 157.38 174.89 0.771 0.442 – –
GAF scores
Total – – 50.18 18.821 64.9 21.101 −3.852 <0.001* – –
Symptoms – – 54.36 20.292 64.98 21.39 −2.641 0.009* – –
Disability – – 51.46 19.092 65.69 19.749 −3.791 <0.001* – –
PANSS
Positive symptoms – – 10.79 3.715 8.55 2.839 3.379 0.001* – –
Negative symptoms – – 8.33 2.116 7.05 0.309 3.906 <0.001* – –
General psychopathology – – 20.89 3.71 17.79 1.828 5.067 <0.001* – –
Total score – – 40.01 7.135 33.38 4.120 5.506 <0.001* – –
YMRS – – 1.56 2.469 3.4 4.607 2.485 0.015* – –
N % N % N % χ2 p χ2 p
Male 28 57.1 38 52.8 17 40.5 1.608 0.205 2.442 0.295
Right-handed 46 93.9 70 97.2 40 97.6 1.148 0.284 1.102 0.576
BD, bipolar disorder; CPZ, chlorpromazine; GAF, global assessment of functioning; HC, healthy controls; PANSS, positive and negative syndrome scale; SCZ,
schizophrenia;WRAT, wide range achievement test; YMRS, young mania rating scale.*p<0.05.
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Table 2 | Neurocognitive functioning across subjects based on brief assessment of cognition battery (BAC).
BAC domains HC (n=49) SCZ (n=72) BD (n=42) ANCOVAa ANCOVAb
All three groups HC vs. SCZ HC vs. BD SCZ vs. BD
Mean SD Mean SD Mean SD F p F p F p F p
Verbal memory 9.07 1.92 7.60 2.11 7.85 1.91 6.45 0.002** 9.84 0.002** 11.99 0.001** 0.92 0.340
Digit sequencing 21.62 3.01 19.04 4.54 18.68 4.07 4.64 0.011* 7.13 0.009* 9.74 0.002** 0.05 0.942
Tokens correct 76.12 12.90 73.46 69.26 64.55 15.97 0.54 0.587 0.12 0.729 10.44 0.002** 0.63 0.430
Tokens left 19.56 12.96 25.57 12.65 26.00 13.60 3.50 0.033* 6.55 0.012* 3.90 0.051 0.32 0.573
Semantic fluency 24.64 5.82 20.10 5.77 21.17 5.86 6.13 0.003** 12.05 0.001** 5.58 0.020* 0.18 0.674
Letter fluency 13.91 3.71 12.51 4.51 12.21 4.82 4.27 0.016* 6.83 0.010* 7.35 0.008* 0.02 0.895
Symbol coding 64.68 10.43 49.21 11.42 50.55 10.45 27.47 <0.001** 48.31 <0.001** 32.85 <0.001** 0.08 0.773
Tower of London 17.04 2.12 16.17 3.79 16.27 3.49 0.24 0.785 0.36 0.548 0.17 0.683 0.08 0.783
BAC total 277.66 28.25 239.36 77.12 232.60 43.69 6.27 0.002** 8.00 0.006* 28.55 <0.001** 0.36 0.552
BAC, brief assessment of cognition battery; BD, bipolar disorder; CPZ, chlorpromazine; GAF, global assessment of functioning; HC, healthy controls; SCZ, schizophrenia;
WRAT, wide range achievement test. *p< 0.05 **p<0.01.
aAdjusted forWRAT, age, gender, and years of education.
bAdjusted for WRAT, age, gender, years of education, duration of untreated psychosis, duration of illness, GAF (total, symptoms, and disability), antipsychotic dose,
and PANSS andYMRS composite scores.
with BD scored lower in BAC tasks of verbal memory, semantic
and letter fluency, digit sequencing, tokens correct, symbol coding,
total BAC score indicating almost similar neurocognitive deficits
as SCZ in verbal memory and fluency, working memory, motor
speed, and attention. After taking into account multiple compar-
isons (at conservative threshold of p< 0.005), patients with SCZ
scored lower on tasks of verbal memory, semantic fluency, sym-
bol coding, and patients with BD scored lower on verbal memory,
digit sequencing, and symbol coding when compared with HC.
However, there was no significant difference in all neurocogni-
tive domains of BAC when SCZ and BD groups were compared and
after controlling for covariates such as demographic characteristics
(age, gender, years of education, WRAT scores) and clinical fea-
tures (duration of untreated psychosis, antipsychotic dose, as well
as GAF, PANSS, and YMRS composite scores). We also noted the
possibility that a history of psychosis in BD patients may be asso-
ciated with poorer performance in neurocognitive tasks compared
to those BD subjects without history of psychosis (30). Thus, we
performed a post hoc analysis whereby we compared BD patients
with history of psychosis and those without and we found no sig-
nificant difference in all neurocognitive performance in all BAC
domains.
Multivariate linear regression analyses with the overall BAC
score as the dependent variable and demographic (age, gender,
education) and clinical factors (diagnosis, WRAT scores, GAF
scores, PANSS composite scores, YMRS scores, duration of illness,
duration of untreated psychosis, antipsychotic dose) as predictor
variables revealed that patients with lower level of psychosocial
functioning as indicated by lower GAF score [F (1,112)= 2.023,
p= 0.046] and older age [F (1, 112)=−2.190, p= 0.031], but not
diagnosis or doses of psychotropic medications, were associated
with poorer overall neurocognitive functioning as measured by
the lower BAC composite score.
DISCUSSION
There were several main findings in this study. First, patients with
BD and SCZ were found to have greater neurocognitive impair-
ments in most of the BAC domains compared to the HC who were
matched for age, gender and premorbid intelligence. Second, the
extensive neurocognitive impairments found in SCZ were com-
parable with those observed in patients with BD. Third, the level
of psychosocial functioning and age of patients with SCZ and BD
were associated with neurocognitive impairment and not diagno-
sis or antipsychotic dose. Our findings highlighted that both SCZ
and BD patients in our study sample suffered largely similar neu-
rocognitive impairments, which support a continuum concept of
psychosis rather than the Kraepelinean concept of dichotomous
psychotic conditions.
Our findings of comparable and extensive neurocognitive
impairments in both SCZ and BD are consistent with some earlier
studies reporting findings of specific neurocognitive impairments
across the patient groups. For example, BD and SCZ patients
scored significantly worse than control subjects in verbal mem-
ory task (assessed by the California Verbal Learning Test), which
did not differ when both patient groups were compared (25, 29).
Likewise, motor speed was also impaired in patients with SCZ/BD
during the Grooved Pegboard test when compared with HC (14,
31). Furthermore, other studies have shown comparable impair-
ments in domains of verbal fluency and working memory within
both SCZ and BD patients (14, 25, 28). In terms of executive func-
tioning, a number of studies found comparable neurocognitive
deficits in both patient groups irrespective of the tests used such
as Wisconsin Card Sorting Test (WCST) (14, 29, 41), Trail Making
Test B (TMT B) (28, 31), and Tower of Hanoi (29). Overall, our
findings add to the literature to support the notion of comparable
and pervasive neurocognitive impairments in patients with BD
and SCZ (17, 29).
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What may be the biological factors that underlie SCZ and BD
which may be relevant to the observed neurocognitive impair-
ments? First, recent evidence from large-scale GWAS has pointed
to possible common susceptibility genes underlying SCZ and BD
which may affect neurocognitive functioning. These common
vulnerability cross disorder genes include ZNF804A, CACNA1C,
NRGN, and PBRM1 (5, 19, 23, 24, 42–45). A recent study from
the Psychiatric Genome Consortium reported that there are 14
genetic loci associated with both SCZ and BD (46), and shared
genetic effects between SCZ and BD accounted for 52% of the
genetic variance in SCZ and 69% for BD in the Swedish popula-
tion (44). Second, neuroimaging aberrations of brain morphology
and function have been noted. For example, voxel-based mor-
phometry studies found that there was a substantial overlap in
gray matter volumetric reductions such as the prefrontal cortex,
thalamus, caudate, medial temporal lobe, insula, and the anterior
cingulate regions in SCZ and BD (7, 15, 47). Third, while genetic
risks for SCZ and BD are associated with different gray matter
changes, McDonald et al. (48) suggested that they share white
matter endophenotypes with the reduction of white matter vol-
ume in the left frontal and temporoparietal regions in both SCZ
and BD.
Of note, older age and poorer psychosocial functioning were
found to be associated with neurocognitive impairments in our
patients. These findings are in line with that of other studies
whereby older age was associated with decreased gray matter vol-
ume (49) and poorer neurocognitive performance in SCZ, and
which can affect psychosocial functioning (50). The lifetime his-
tory of psychotic features in BD patients has also been found to
worsen subsequent neurocognitive performance such as cognitive
flexibility and working memory indicating age related effects on
neurocognitive functioning in BD (10, 26, 27, 30, 32, 51). However,
in contrast, Gildengers et al. (52) found no difference in the rate of
neurocognitive decline between BD and healthy subjects with age.
We found that antipsychotic medication dose was not associ-
ated with neurocognitive impairment in SCZ and BD in this study
although there is evidence of antipsychotic medications affect-
ing changes in brain structures and neurocognitive performance.
Previous studies have reported both improvements in neurocog-
nitive impairments with antipsychotic treatment in SCZ and BD
(26) but negative impact on cognition have also been reported
in BD (53, 54). In SCZ patients, some studies reported that the
administration of typical antipsychotic medication provides only
modest-to-moderate gains in multiple cognitive domains (55, 56),
while other studies found no correlation between antipsychotic
medication dose and neurocognitive functioning in BD and SCZ
(9, 18, 57).
Recent data also suggest that neurocognitive deficits may poten-
tially serve as endophenotypical trait markers for BD and SCZ
(58–60). Unlike a state marker whereby neurocognitive perfor-
mance may vary with and be influenced by current clinical states
such as affective change and psychotic phenomenology, a trait
marker remains stable throughout the illness course and may be
related to genetic factors (60, 61). For SCZ, a twin study by Pardo
et al. (58) noted preservative errors on the WCST not only in the
SCZ twin but also within non-SCZ monozygotic co-twin suggest-
ing a spectrum of genetic liability. Furthermore, clinical symptoms
do not seem to play a role in worsening cognitive performance in
ultra-high risk of psychosis subjects (62). In BD, Sobzcak et al. (59)
found deficits in memory function, psychomotor performance
and attention in high risk relatives suggesting potential neurocog-
nitive trait markers for BD. In a recent longitudinal study involving
BD patients, the severity of depressive symptoms did not predict
change of performance in any cognitive domains and all domains
remained stable over the course of 6 years (60).
There are several limitations to the study. First, our sample
size was rather small and the study solely recruited patients with
remitted SCZ and BD seen at the outpatient setting of a tertiary
psychiatric hospital and thus the results may not be generalizable
to patients within the inpatient and in non-tertiary psychiatric
settings. Second, this was a cross-sectional study and did not allow
observations of changes of neurocognitive functioning over the
course of time. Third, the administrators of the neurocognitive
tests were not blinded to the diagnoses of the subjects. Lastly, we
did not examine other biological correlates such as genetic fac-
tors, neurophysiological measures but we intend to do so as a
follow up study of these findings. These multimodality studies
can potentially elucidate biological underpinnings or correlates of
these neurocognitive impairments in SCZ and BD.
In conclusion, we found that patients with BD and SCZ suffer
widespread neurocognitive deficits involving almost all the exam-
ined cognitive domains. The severity of neurocognitive deficits has
been found to be significantly associated with various factors such
as the level of psychosocial functioning and age but not specific
diagnoses or antipsychotic medications. The underlying biologi-
cal basis of these neurocognitive deficits may be related to factors
common to both conditions and awaits better definition. Our
findings support the dimensional concept of psychotic spectrum
conditions along a continuum rather than the dichotomous con-
cept as proposed by Kraepelin. Although DSM-V (63) still retains
the existing nosological boundaries between BD and SCZ, clini-
cians would have to remain vigilant in managing each case of SCZ
or BD by taking into account their clinical, socio-demographic
factors, and assessing for the presence of specific neurocogni-
tive impairment so as to better optimize the care and cater for
more individually tailored treatment plans for these patients with
potentially crippling conditions.
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